X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Avacc 10 consists of Outer Membrane. Vesicles (OMV) derived from the bacterium N. meningitidis that are mixed with the stabilized spike protein of SARS-CoV-2. It is an intranasal vaccine designed as a booster vaccine to prevent COVID-19.
Lead Product(s): Avacc 10
Therapeutic Area: Infections and Infectious Diseases Product Name: Avacc 10
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
The proceeds will be used for the development of a preventive vaccine, Avacc 11, against Neisseria gonorrhoeae (NG). This vaccine will be developed on Intravacc’s proprietary outer membrane vesicle (OMV) platform technology.
Lead Product(s): Avacc 11
Therapeutic Area: Infections and Infectious Diseases Product Name: Avacc 11
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: CARB-X
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Funding January 16, 2024
Details:
Avacc 11 (gonorrhea vaccine avacc 11) is the prophylactic intranasal gonorrhea candidate vaccine, consisting of outer membrane vesicles and microsphere encapsulated interleukin-12 induced Th1-driven immunity, with circulating and genital antibodies to Neisseria gonorrhoeae.
Lead Product(s): Gonorrhea Vaccine Avacc 11
Therapeutic Area: Infections and Infectious Diseases Product Name: Avacc 11
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2023
Details:
The phase I clinical trial has just commenced in a clinical center in Australia, and will assess the tolerability, safety and immunogenicity of the intranasal Avacc 10® vaccine. Avacc 10® is based on Intravacc's proprietary outer membrane vesicles (OMV) platform.
Lead Product(s): Avacc 10
Therapeutic Area: Infections and Infectious Diseases Product Name: Avacc 10
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Avacc 101 is Intravacc subunit betacoronavirus vaccine candidate. Avacc 101 vaccine candidate will be designed to provide broad protection against SARS-CoV-1, SAR-CoV-2, and MERS-CoV.
Lead Product(s): Avacc 101
Therapeutic Area: Infections and Infectious Diseases Product Name: Avacc 101
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: EpiVax
Deal Size: $4.8 million Upfront Cash: Undisclosed
Deal Type: Collaboration November 01, 2022
Details:
CEPI’s funding will support preclinical development and testing of Intravacc’s subunit vaccine candidate Avacc 101, which is based on its Outer Membrane Vesicle (OMV) platform.
Lead Product(s): Avacc 101
Therapeutic Area: Infections and Infectious Diseases Product Name: Avacc 101
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: $4.8 million Upfront Cash: Undisclosed
Deal Type: Funding October 06, 2022
Details:
The grant will support the NG vaccine, called NGoXIM, based on gonococcal OMVs combined with sustained-release microspheres containing recombinant human IL-12, and will be administered intranasally.
Lead Product(s): Recombinant Human IL-12
Therapeutic Area: Infections and Infectious Diseases Product Name: NGoXIM
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $14.6 million Upfront Cash: Undisclosed
Deal Type: Funding October 05, 2022
Details:
DZNE developed an experimental vaccine that instructs the immune system to produce antibodies against these harmful poly-GA molecules. In a mouse model, this reduces poly-GA aggregates and largely prevents motor deficits.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: European Union
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Funding July 06, 2022
Details:
Both parties will continue to collaborate to tailor the Avacc 3 concept vaccine for the respective territories, including upscaling, toxicology and clinical trials. Avacc 3 has significant advantages over existing whooping cough vaccines.
Lead Product(s): Avacc-3
Therapeutic Area: Infections and Infectious Diseases Product Name: Avacc-3
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Beijing Zhifei Lvzhu Biopharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 02, 2022
Details:
The results of the first-in-human trial for the SF2a-TT15, semi-synthetic glycan-based conjugate vaccine candidate against Shigella flexneri 2a, developed at the Institut Pasteur demonstrated safety and immunogenicity.
Lead Product(s): SF2a-TT15
Therapeutic Area: Infections and Infectious Diseases Product Name: SF2a-TT15
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Institut Pasteur
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
